VT
ALNY icon

Volterra Technologies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Volterra Technologies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-490
Closed -$160K – 343
2025
Q2 		$160K Buy
+490
New +$136K 0.02% 366

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Volterra Technologies's ALNY Position: Q3 2025 in Review

Volterra Technologies sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 490 shares — an estimated $160K sold.

Volterra Technologies first reported a position in ALNY in Q2 2025 and held it in 1 quarter. The position peaked at $160K in Q2 2025. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Volterra Technologies reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Volterra Technologies sold 490 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $160K.
  • Volterra Technologies first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Volterra Technologies's Alnylam Pharmaceuticals position peaked at $160K in Q2 2025.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Volterra Technologies's 13F filing for Q3 2025, filed 14 Nov 2025.